Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.40 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
| ▸ | PDE2A | O00408 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 4/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1482770 | 0.91 | KCNH2 (0.41) | KCNH2NR1H4SOS1SLC6A4HTR6 | |
| SCHEMBL1482691 | 0.88 | NR1H4 (0.44) | KCNH2TRPV4NR1H4CNR1CNR2 | |
| SCHEMBL1484274 | 0.88 | CCR2 (0.42) | KCNH2NR1H4SLC6A4 | |
| SCHEMBL1483024 | 0.87 | DHFR (0.43) | KCNH2NR1H4SLC6A4HTR6CYP11B1 | |
| SCHEMBL1482610 | 0.87 | KMT2A (0.43) | KCNH2NR1H4SLC6A4HTR6CYP11B1 | |
| SCHEMBL1482474 | 0.86 | CNR1 (0.39) | CNR1CNR2SOS1 | |
| SCHEMBL1483043 | 0.84 | NR1H4 (0.37) | KCNH2NR1H4SLC6A4HTR6CYP11B1 | |
| SCHEMBL1482104 | 0.84 | PTGER1 (0.45) | KCNH2NR1H4 | |
| SCHEMBL1482645 | 0.84 | NR1H4 (0.48) | KCNH2NR1H4 | |
| SCHEMBL1482217 | 0.84 | NR1H4 (0.38) | KCNH2NR1H4SLC6A4HTR6CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309581-B2 | Benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20110077273-A1 | NEW BENZIMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077273-A1 | NEW BENZIMIDAZOLE DERIVATIVES | BRI3BP, CYP3A4, RB1 | KCNH2 839/4885TRPV4 1195/4885NR1H4 776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.